Arrowhead Pharmaceuticals to Present Preclinical Data on Emerging Pipeline of RNAi Therapeutics

Investors

<<  Back

Arrowhead Pharmaceuticals to Present Preclinical Data on Emerging Pipeline of RNAi Therapeutics

May 1, 2018 at 7:30 AM EDT

PASADENA, Calif. --(BUSINESS WIRE)--May 1, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present preclinical data on ARO-ANG3 and ARO-APOC3, its two candidates targeting cardiometabolic diseases, and ARO-ENaC, formerly referred to as ARO-Lung1, its first

PASADENA, Calif.--(BUSINESS WIRE)--May 1, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present preclinical data on ARO-ANG3 and ARO-APOC3, its two candidates targeting cardiometabolic diseases, and ARO-ENaC, formerly referred to as ARO-Lung1, its first candidate to leverage the Targeted RNAi Molecule (TRiMTM) platform to address diseases in the lung. Arrowhead will deliver presentations at the following conferences:

Vascular Discovery: From Genes to Medicine – Scientific Sessions 2018 San Francisco, May 10-12, 2018

May 10, 4:15 p.m. PDTBruce Given, M.D., Arrowhead’s chief operating officer and head of R&D, will deliver an invited lecture titled, “The promise of RNA interference as a therapeutic approach for treatment of cardiovascular diseases.” In this presentation, Dr. Given will discuss the use of RNAi broadly in treating cardiovascular diseases, including preclinical data on ARO-ANG3 targeting angiopoietin-like protein 3 (ANGPTL3) and ARO-APOC3 targeting apolipoprotein C-III (apoC-III), Arrowhead’s preclinical candidates for the treatment of cardiometabolic diseases.

American Thoracic Society (ATS) 2018 International ConferenceSan Diego, May 18-23, 2018

May 21, 9:15 a.m.-4:15 p.m. PDTErik Bush, Ph.D., Arrowhead’s director of extra-hepatic targeting, will deliver a poster presentation titled, “Targeting αENaC with an epithelial RNAi trigger delivery platform for the treatment of cystic fibrosis.” In this presentation, Dr. Bush will present new preclinical data on ARO-ENaC, formerly referred to as ARO-Lung1, targeting the epithelial sodium channel alpha subunit (αENaC) for the treatment of cystic fibrosis.

A copy of presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website after the presentations conclude.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Source: Arrowhead Pharmaceuticals, Inc.

Source: Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com
or
Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie, 212-915-2578
britchie@lifesciadvisors.com
www.lifesciadvisors.com